Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

11.05 +0.28 (+2.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,561,413
Open 10.75
Bid (Size) 11.10 (2)
Ask (Size) 11.25 (9)
Prev. Close 10.77
Today's Range 10.54 - 11.25
52wk Range 6.080 - 11.93
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks. 
Via InvestorPlace

Performance

YTD
+30.92%
+30.92%
1 Month
+32.97%
+32.97%
3 Month
+25.14%
+25.14%
6 Month
+17.06%
+17.06%
1 Year
+12.41%
+12.41%

More News

Read More
Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year
Via InvestorPlace
The 3 Best Gene Editing Stocks on the Frontier of Medicine
Via InvestorPlace
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Via The Motley Fool
A Preview Of Editas Medicine's Earnings
Via Benzinga
Analyst Ratings for Editas Medicine
Via Benzinga
3 Long-Term Growth Stocks Analysts Are Bullish On
Via InvestorPlace
3 Biotech Stocks That Are Betting on the Future of Gene Editing
Via InvestorPlace
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Earnings Scheduled For November 3, 2023
Via Benzinga
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
Via The Motley Fool
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Via Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
Via Benzinga
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
Via The Motley Fool
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
NetScout Systems, Ericsson And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.